*R42 Longevity Series* lecture two is today, *Wednesday at 10am PT / 6pm BST / 7pm CET!*
*Topic:* Therapeutic Reversal of Brain Aging and Neurodegeneration.
*Lecturer:* Dr. Judith Kelleher-Andersson - Has over twenty years of experience developing small-molecule, central nervous system therapeutics in the biotechnology industry. She founded Neuronascent, raised equity, obtained State and Federal funding to discover novel therapies that address chronic neurodegenerative disorders. One of these is now a clinical stage, patented, first-in-category therapy to reverse age-related disorders. Prior to founding Neuronascent, she was Director of Drug Development and Research at Neuralstem, Inc., Centaur Pharmaceuticals and Scientist at Cortex Pharmaceuticals, Inc. She headed the Alzheimer’s disease program in collaboration with Astra (later AstraZeneca) while at Centaur, and successfully brought a small-molecule agent to pre- nomination status. She invented a neurogenic depression therapeutic that has now completed Phase IIb, while at Neuralstem. Dr. Kelleher-Andersson has over 70 US, European and World patents. She received a B.A. in chemistry from St. Anselms College, her Ph.D. in biochemistry from University of Missouri-Columbia and completed post-graduate work at UCLA with a Mental Retardation Fellowship and at University of California, San Francisco in the Neurology Dept.
*Format:* Lecture by Dr. Judith Kelleher-Andersson, Q&A moderated by Dr. Ronjon Nag and Anastasiya Giarletta (), Breakout Rooms
(please, register in advance)
*Topic:* Therapeutic Reversal of Brain Aging and Neurodegeneration.
*Lecturer:* Dr. Judith Kelleher-Andersson - Has over twenty years of experience developing small-molecule, central nervous system therapeutics in the biotechnology industry. She founded Neuronascent, raised equity, obtained State and Federal funding to discover novel therapies that address chronic neurodegenerative disorders. One of these is now a clinical stage, patented, first-in-category therapy to reverse age-related disorders. Prior to founding Neuronascent, she was Director of Drug Development and Research at Neuralstem, Inc., Centaur Pharmaceuticals and Scientist at Cortex Pharmaceuticals, Inc. She headed the Alzheimer’s disease program in collaboration with Astra (later AstraZeneca) while at Centaur, and successfully brought a small-molecule agent to pre- nomination status. She invented a neurogenic depression therapeutic that has now completed Phase IIb, while at Neuralstem. Dr. Kelleher-Andersson has over 70 US, European and World patents. She received a B.A. in chemistry from St. Anselms College, her Ph.D. in biochemistry from University of Missouri-Columbia and completed post-graduate work at UCLA with a Mental Retardation Fellowship and at University of California, San Francisco in the Neurology Dept.
*Format:* Lecture by Dr. Judith Kelleher-Andersson, Q&A moderated by Dr. Ronjon Nag and Anastasiya Giarletta (), Breakout Rooms
(please, register in advance)
